From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor
Abstract
BACKGROUND: Osmotic nephropathy is an infrequent drug‑induced complication characterized by vacuolization of renal tubular cells secondary to lysosomal uptake, which increases osmotic pressure within the proximal tubule. This lesion pattern has been linked to administration of intravenous immunoglobulins, iodinated contrast agents, mannitol, dextrans and glucose solutions, and more recently to the use of sodium-glucose cotransporter‑2 (SGLT2) inhibitors.
CASE PRESENTATION: A 49‑year‑old man with a history of hypertension, type 2 diabetes mellitus and obesity, chronically treated with empagliflozin, presented with diarrhea, abdominal pain and oliguria. Laboratory tests revealed acute kidney injury with a serum creatinine of 13 mg/dL and electrolyte disturbances. In light of a suspected rapidly progressive glomerulonephritis, renal replacement therapy was initiated owing to failure of hydration. Renal biopsy showed diffuse tubular vacuolization compatible with osmotic nephropathy, leading to discontinuation of the SGLT2 inhibitor. The patient's renal function recovered after two weeks of hemodialysis.
CONCLUSIONS: Osmotic nephropathy is a rare histopathological diagnosis associated with exposure to hyperosmolar agents, as exemplified by this case related to empagliflozin use. The proposed pathophysiological mechanism involves lysosomal uptake secondary to increased intratubular osmotic pressure caused by glucosuria. Predisposing factors include therapy with SGLT2 inhibitors,…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.